Key terms
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VKTX news
Apr 16
11:10pm ET
LLY, VKTX, or NVO: Which Weight-Loss Drugmaker Could Gain the Best Returns?
Apr 08
8:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 05
12:40pm ET
Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap
Mar 29
3:05am ET
Buy Rating Affirmed for Viking Therapeutics Amid Promising Obesity Drug Trials and Strategic Market Positioning
Mar 28
6:25am ET
3 Best Stocks to Buy Now, 3/28/2024, According to Top Analysts
Mar 27
10:05pm ET
Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX)
Mar 27
7:53am ET
Viking Therapeutics price target raised to $138 from $116 at Oppenheimer
Mar 26
3:25pm ET
Buy Rating Affirmed for Viking Therapeutics on Strong Clinical Outcomes and Promising Obesity Program
Mar 26
3:12pm ET
Viking Therapeutics price target raised to $138 from $116 at Oppenheimer
Mar 26
12:09pm ET
Viking Therapeutics price target raised to $125 from $100 at BTIG
Mar 26
10:55am ET
Buy Rating Affirmed for Viking Therapeutics on Strong Phase 1 Results of Weight Loss Candidate VK2735
Mar 26
7:22am ET
Viking Therapeutics Clarifies Regulatory Disclosure Status
Mar 16
7:45am ET
Buy Rating Affirmed for Viking Therapeutics: Promising NASH Treatments and Competitive Edge in Metabolic Disease Pipeline
Mar 15
7:17am ET
Approval of Madrigal’s Rezdiffra positive for Viking and MASH space, says Stifel
Mar 15
7:14am ET
Viking Therapeutics price target raised to $100 from $86 at BTIG
Mar 11
12:47am ET
Maintaining Buy on Viking Therapeutics: Overreaction to Competitor’s Data and Confidence in VK2735’s Market Potential
Mar 08
7:15am ET
Truist Financial Gives a Buy Rating to Viking Therapeutics (VKTX)
Mar 08
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
Mar 07
3:34pm ET
Novo results raising the bar for Viking’s oral VK2735, says Oppenheimer
Mar 07
4:52am ET
Viking Therapeutics initiated with a Buy at Jefferies
Mar 07
4:21am ET
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Boston Scientific (BSX)
Mar 03
5:25am ET
BTIG Sticks to Its Buy Rating for Viking Therapeutics (VKTX)
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Mar 01
9:40am ET
Unusually active option classes on open March 1st
Mar 01
7:31am ET
Viking Therapeutics price target raised to $120 from $38 at Truist
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:39am ET
Viking Therapeutics price target raised to $120 from $38 at Truist
Feb 29
9:40am ET
Unusually active option classes on open February 29th
Feb 28
9:04pm ET
Viking Therapeutics 6.47M share Secondary priced at $85.00
Feb 28
7:38am ET
Viking Therapeutics price target raised to $116 from $46 at Oppenheimer
No recent press releases are available for VKTX
VKTX Financials
Key terms
Ad Feedback
VKTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VKTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range